Immune checkpoint inhibitors (ICIs) for programmed cell death 1 (PD‐1)/programmed cell death‐ligand 1 (PD‐L1) blockade have become one of the effective treatments for advanced non‐small cell lung cancer (NSCLC).1 This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.